keyword
MENU ▼
Read by QxMD icon Read
search

I-131 Therapy

keyword
https://www.readbyqxmd.com/read/28898346/-treatment-of-hyperthyroidism-with-radioiodine-during-hemodialysis-report-of-one-case
#1
Claudia Hurtado, María Soledad Báez, Anabel Bate, Claudio Opazo, Mauricio Troncoso
Although radioiodine (131-I) can be used as treatment of hyperthyroidism for patients in hemodialysis, its use is limited and the experience is mainly related to differentiated thyroid carcinoma. We report a 58 years old female on hemodialysis with recurrent hyperthyroidism after propylthiouracil treatment. She was successfully treated with 131-I and four months after the intervention her euthyroid state was confirmed. We measured 131-I activity in blood, dialysate liquid and other waste products, as well as patient radiation exposure rates...
May 2017: Revista Médica de Chile
https://www.readbyqxmd.com/read/28895066/the-effect-of-short-term-treatment-with-lithium-carbonate-on-the-outcome-of-radioiodine-therapy-in-patients-with-long-lasting-graves-hyperthyroidism
#2
Vladan Sekulić, Milena Rajić, Marina Vlajković, Slobodan Ilić, Miloš Stević, Marko Kojić
OBJECTIVE: The outcome of radioiodine therapy (RIT) in Graves' hyperthyroidism (GH) mainly depends on radioiodine ((131)I) uptake and the effective half-life of (131)I in the gland. Studies have shown that lithium carbonate (LiCO3) enhances the (131)I half-life and increases the applied thyroid radiation dose without affecting the thyroid (131)I uptake. We investigated the effect of short-term treatment with LiCO3 on the outcome of RIT in patients with long-lasting GH, its influence on the thyroid hormones levels 7 days after RIT, and possible side effects...
September 11, 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/28887837/characterisation-of-proton-pencil-beam-scanning-and-passive-beam-using-a-high-spatial-resolution-solid-state-microdosimeter
#3
Linh T Tran, Lachlan Chartier, David Bolst, Alex Pogossov, Susanna Guatelli, Marco Petasecca, Michael L F Lerch, Dale A Prokopovich, Mark I Reinhard, Benjamin Clasie, Nicolas Depauw, Hanne Kooy, Jacob B Flanz, Aimee McNamara, Harald Paganetti, Chris Beltran, Keith Furutani, Vladimir L Perevertaylo, Michael Jackson, Anatoly B Rosenfeld
PURPOSE: This work aims to characterise a proton pencil-beam scanning (PBS) and passive double scattering (DS) systems as well as to measure parameters relevant to the relative biological effectiveness (RBE) of the beam using a silicon-on-insulator (SOI) microdosimeter with well-defined 3D sensitive volumes (SV). The dose equivalent downstream and laterally outside of a clinical PBS treatment field was assessed and compared to that of a DS beam. METHODS: A novel silicon microdosimeter with well-defined 3D SVs was used in this study...
September 8, 2017: Medical Physics
https://www.readbyqxmd.com/read/28878853/bilateral-renal-metastasis-of-h%C3%A3-rthle-cell-thyroid-cancer-with-discordant-uptake-between-i-131-sodium-iodide-and-f-18-fdg
#4
Apichaya Claimon, Minseok Suh, Gi Jeong Cheon, Dong Soo Lee, E Edmund Kim, June-Key Chung
Renal metastasis of thyroid cancer is extremely rare. We report the case of a 62-year-old woman with Hürthle cell thyroid cancer (HCTC) with lungs, bones, and bilateral kidneys metastases. The renal metastatic lesions were clearly demonstrated by (131)I whole body scan (WBS) with SPECT/CT. However, they exhibited false-negative results in (18)F-FDG PET/CT, kidney ultrasonography, and contrast-enhanced CT scan. The findings imply that tumors have low glucose metabolism and are able to accumulate radioiodine, which is not commonly found in the relatively aggressive nature of HCTC...
September 2017: Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28871998/peripheral-blood-biomarkers-associated-with-toxicity-and-treatment-characteristics-after-131-i-metaiodobenzylguanidine-therapy-in-patients-with-neuroblastoma
#5
Kevin Campbell, Erin E Karski, Aleksandra Olow, David A Edmondson, Ayano C Kohlgruber, Matthew Coleman, Daphne A Haas-Kogan, Katherine K Matthay, Steven G DuBois
PURPOSE: Few tools exist to predict clinical outcomes after radiopharmaceutical therapy. Our goal was to identify associations between blood-based biomarkers of radiation effect and clinical outcomes after (131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy in patients with neuroblastoma. METHODS AND MATERIALS: We conducted a prospective, single-center cohort study in children with advanced neuroblastoma treated with (131)I-MIBG as monotherapy or in combination with systemic putative radiation sensitizers...
October 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28867113/precision-medicine-and-pet-computed-tomography-in-pediatric-malignancies
#6
REVIEW
Yasemin Sanli, Ebru Yilmaz, Rathan M Subramaniam
Fluorine-18 fluorodeoxyglucose ((18)F-FDG) PET-computed tomography (CT) plays a significant role in diagnosis, staging, therapy selection, and therapy assessment of multiple pediatric malignancies and facilitating precision medicine delivery in pediatric patients. In patients with Hodgkin lymphoma, interim fludeoxyglucose (18)F-FDG PET/CT is highly sensitive and specific for predicting survival and multiple trials with FDG PET/CT-based adaptive therapies are currently ongoing. It is superior to iodine-131 metaiodobenzylguanidine ((131)I-MIBG) scintigraphy and bone scintigraphy for detecting metastases in neuroblastoma patients and sarcoma patients...
October 2017: PET Clinics
https://www.readbyqxmd.com/read/28864631/radionuclide-tumor-targeting-using-adapt-scaffold-proteins-aspects-of-label-positioning-and-residualizing-properties-of-the-label
#7
Sarah Lindbo, Javad Garousi, Bogdan Mitran, Mohamed Altai, Jos Buijs, Anna Orlova, Sophia Hober, Vladimir Tolmachev
Visualization of cancer-associated alterations of molecular phenotype using radionuclide imaging is a non-invasive approach to stratify patients for targeted therapies. The engineered scaffold protein ABD-.derived affinity protein (ADAPT) is a promising tracer for radionuclide molecular imaging due to its small size (6.5 kDa), that provides precondition for efficient tumor penetration and rapid clearance. Previous studies demonstrated that the human epidermal growth factor receptor type 2 (HER2)-targeting ADAPT6 labeled with radiometals at the N-terminus provides imaging of HER2 expression in xenografts a few hours after injection...
September 1, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28864620/individualized-dosimetry-for-theranostics-necessary-nice-to-have-or-counterproductive
#8
Uta Eberlein, Marta Cremonesi, Michael Lassmann
In 2005, the term theragnostics (theranostics) was introduced for describing the use of imaging for therapy planning in radiation oncology. In nuclear medicine, this expression describes the use of tracers for predicting the absorbed doses in molecular radiotherapy and, thus, the safety and efficacy of a treatment. At present, the most successful groups of isotopes for this purpose are (123)I/(124)I/(131)I, (68)Ga/(177)Lu, and (111)In/(86)Y/(90)Y. The purpose of this review is to summarize available data on the dosimetry and dose-response relationships of several theranostic compounds, with a special focus on radioiodine therapy for differentiated thyroid cancer and peptide receptor radionuclide therapy...
September 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28864611/norepinephrine-transporter-as-a-target-for-imaging-and-therapy
#9
Neeta Pandit-Taskar, Shakeel Modak
The norepinephrine transporter (NET) is essential for norepinephrine uptake at the synaptic terminals and adrenal chromaffin cells. In neuroendocrine tumors, NET can be targeted for imaging as well as therapy. One of the most widely used theranostic agents targeting NET is metaiodobenzylguanidine (MIBG), a guanethidine analog of norepinephrine. (123)I/(131)I-MIBG theranostics have been applied in the clinical evaluation and management of neuroendocrine tumors, especially in neuroblastoma, paraganglioma, and pheochromocytoma...
September 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28860813/low-versus-high-radioiodine-activity-for-ablation-of-the-thyroid-remnant-after-thyroidectomy-in-han-chinese-with-low-risk-differentiated-thyroid-cancer
#10
Rong-Bin Lv, Qing-Gang Wang, Chao Liu, Fang Liu, Qing Zhao, Jian-Guo Han, Dao-Ling Ren, Bin Liu, Cheng-Li Li
AIM: The aim of this study was to compare the efficacy and adverse effects of radioiodine ((131)I) therapy between two groups of patients with low-risk differentiated thyroid cancer (DTC) who received 30 mCi or 100 mCi radioiodine for ablation of the thyroid remnant after total thyroidectomy. METHODS: The study cohort was 173 patients, 85 of whom were given 30 mCi of radioiodine and the others were given 100 mCi of radioiodine. Follow-up involved neck ultrasonography, measurement of serum levels of thyroglobulin and whole-body scans to evaluate the response of radioiodine treatment...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28834790/comparison-of-treatment-efficacy-1-and-2-years-after-thyroid-remnant-ablation-with-1110-versus-5550%C3%A2-mbq-of-iodine-131-in-patients-with-intermediate-risk-differentiated-thyroid-cancer
#11
Atena Aghaei, Narjess Ayati, Susan Shafiei, Bita Abbasi, S Rasoul Zakavi
BACKGROUND: Radioiodine ablation may be associated with improved survival in patients with intermediate-risk follicular cell differentiated thyroid cancer (FCDTC). The aim of this study was to compare ablation efficacy of 1110 versus 5500 MBq of iodine-131 (I) in FCDTC patients with intermediate risk. METHODS: Thirty-nine patients with intermediate-risk FCDTC (T3N0, T1-2N1b and T1-3N1a) were treated with 1110 MBq of I and compared with 43 age-matched and sex-matched patients who received 5550 MBq of I...
August 22, 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28815788/association-between-radioiodine-treatment-for-thyroid-cancer-and-risk-of-stroke
#12
Chun-Yi Lin, Cheng-Li Lin, Yi-Chen Lo, Chia-Hung Kao
BACKGROUND: The purpose of this study was to evaluate the association between radioiodine (I-131) therapy for thyroid cancer and the risk of stroke in Taiwan. METHODS: A total of 10 104 of the patients aged 20 years or older, who were newly diagnosed with thyroid cancer during 2000-2010, were recruited and classified into 2 cohorts according to whether they received I-131 therapy through 1:1 propensity score matching. The cumulative Kaplan-Meier curves for the incidence of stroke in the 2 cohorts were compared using the log-rank test...
August 16, 2017: Head & Neck
https://www.readbyqxmd.com/read/28814251/the-role-of-radiopharmaceuticals-in-amiodarone-induced-thyroid-pathology
#13
Doina Piciu, Alexandru Irimie
Amiodarone is a di-iodinated benzofuran derivative and is classified as a class III antiarrhythmic agent. It is one of the most powerful and effective antiarrhythmics, being a first-line agent due to its ability to treat ventricular and supraventricular dysrhythmias; since 1960 the drug has become one of the most frequently prescribed antiarrhythmics, despite its potentially serious, side effects. By far, one of the most challenging condition is the thyroid pathology induced by this drug. Each 200 mg tablet of amiodarone contains approximately 75 mg of iodine, 3-10% from each tablet being released as free iodine...
August 16, 2017: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/28811561/analysis-of-risk-factors-of-rapid-thyroidal-radioiodine-131-turnover-in-graves-disease-patients
#14
Ruiguo Zhang, Jian Tan, Renfei Wang, Guizhi Zhang, Qiang Jia, Zhaowei Meng, Yueqian Zhang
Rapid iodine-131((131)I) turnover in the thyroid gland is an important feature of Graves' disease (GD) and also a strong predictor of radioiodine therapy failure. The aim of this study was to explore the predictors of rapid (131)I turnover. The clinical data on 2543 patients were retrospectively reviewed. Patients were divided into 2 groups depending on present or absent with rapid (131)I turnover defined as a 4-hour to 24-hour (131)I uptake ratio of ≥1. Overall, 590 cases (23.2%) had a rapid (131)I turnover...
August 15, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28798811/pregnancy-testing-in-patients-undergoing-radiation-therapy
#15
Shivam M Kharod, Julie Greenwalt, Camille Dessaigne, Anamaria Yeung
Radiation therapy (RT) can be lethal to a developing fetus; therefore, determining pregnancy status before RT is essential. We here sought to determine how many women treated with RT at our institution for over one year were at risk for pregnancy when starting RT. We retrospectively reviewed the medical records of all female patients 12-55 years old treated with radiation, i.e. 1 October 2012 to 31 September 2013. Patients were categorised as 'at risk' if they had a uterus and 'no risk' if they had a hysterectomy...
2017: Ecancermedicalscience
https://www.readbyqxmd.com/read/28792635/favorable-results-in-abo-incompatible-renal-transplantation-without-b-cell-targeted-therapy-advantages-and-disadvantages-of-rituximab-pretreatment
#16
Manabu Okada, Yoshihiko Watarai, Kenta Iwasaki, Kenta Murotani, Kenta Futamura, Takayuki Yamamoto, Takahisa Hiramitsu, Makoto Tsujita, Norihiko Goto, Shunji Narumi, Asami Takeda, Kunio Morozumi, Kazuharu Uchida, Takaaki Kobayashi
The effectiveness of desensitization with rituximab in ABO-incompatible renal transplantation (ABO-I) has been widely reported. However, ABO-I outcomes are still worse than those of ABO-identical or ABO-compatible renal transplantation (ABO-Id/C). We retrospectively examined the outcomes in consecutive living donor ABO-Id/C (n = 412) and ABO-I (n = 205) cases to elucidate the causes of inferiority in ABO-I. ABO-I cases included recipients treated with rituximab (RIT, n = 131), splenectomy (SPX, n = 21), or neither because of low anti-A/B antibody titers (NoR/S, n = 53)...
August 9, 2017: Clinical Transplantation
https://www.readbyqxmd.com/read/28776731/correlations-of-ctla-4-exon-1-49-a-g-and-promoter-region-318%C3%A2-c-t-polymorphisms-with-the-therapeutic-efficacy-of-131-i-radionuclide-in-graves-disease-in-chinese-han-population
#17
Xin-Rui Han, Xin Wen, Shan Wang, Shao-Hua Fan, Juan Zhuang, Yong-Jian Wang, Zi-Feng Zhang, Meng-Qiu Li, Bin Hu, Qun Shan, Chun-Hui Sun, Ya-Xing Bao, Sha Luan, Chang-Jiu Zhao, Dong-Mei Wu, Jun Lu, Yuan-Lin Zheng
This study aimed to investigate the correlation of CTLA-4 exon-1 49 A/G and promoter region-318 C/T polymorphisms with the therapeutic efficacy of radionuclide (131) I for Graves' disease in Chinese Han population. The (131) I radionuclide therapy was applied in 261 patients with Graves' disease. The patients were classified into the remission and non-remission groups. PCR-RFLP was implemented to detect CTLA-4 exon-1 49 A/G and promoter region-318 C/T polymorphisms. Haplotypes of CTLA-4 49 A/G and -318 C/T were analyzed using SHEsis software online...
August 4, 2017: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/28751451/131i-labeled-anti-her2-camelid-sdab-as-a-theranostic-tool-in-cancer-treatment
#18
Matthias D'Huyvetter, Jens De Vos, Catarina Xavier, Marek Pruszynski, Yann G J Sterckx, Sam Massa, Geert Raes, Vicky Caveliers, Michael Zalutsky, Tony Lahoutte, Nick Devoogdt
<p>Camelid single-domain antibody-fragments (sdAbs) have beneficial pharmacokinetic properties, and those targeted to HER2 can be used for imaging of HER2-overexpressing cancer. Labeled with a therapeutic radionuclide, they may be used for HER2-targeted therapy. Here we describe the generation of a (131)I-labeled sdAb as a theranostic drug to treat HER2-overexpressing cancer.</p> <br />Experimental Design: <p>Anti-HER2 sdAb 2Rs15d was labeled with (131)I using [(131)I]SGMIB and evaluated in vitro Biodistribution was evaluated in two HER2(+) murine xenograft models by micro-SPECT/CT imaging and at necropsy, and under challenge with trastuzumab and pertuzumab...
July 27, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28736501/design-of-radioiodinated-pharmaceuticals-structural-features-affecting-metabolic-stability-towards-in-vivo-deiodination
#19
REVIEW
Lorenzo Cavina, Dion van der Born, Peter H M Klaren, Martin C Feiters, Otto C Boerman, Floris P J T Rutjes
Radioiodinated pharmaceuticals are convenient tracers for clinical and research investigations because of the relatively long half-lives of radioactive iodine isotopes (i.e., (123)I, (124)I, and (131)I) and the ease of their chemical insertion. Their application in radionuclide imaging and therapy may, however, be hampered by poor in vivo stability of the C-I bond. After an overview of the use of iodine in biology and nuclear medicine, we present here a survey of the catabolic pathways for iodinated xenobiotics, including their biodistribution, accumulation, and biostability...
June 30, 2017: European Journal of Organic Chemistry
https://www.readbyqxmd.com/read/28719405/clinical-outcomes-1-year-after-empiric-131i-therapy-for-hyperthyroid-disorders-real-life-experience-and-predictive-factors-of-functional-response
#20
Lavinia Vija Racaru, Charlotte Fontan, Mathilde Bauriaud-Mallet, Séverine Brillouet, Olivier Caselles, Slimane Zerdoud, Delphine Bastié, Delphine Vallot, Philippe Caron, Manuel Bardiès, Frederic Courbon
: Radioiodine is a therapeutic option in Europe for Graves' disease (GD) and toxic multinodular goiter (MNG). PURPOSE: To compare empiric and calculated I activities using 2013 EANM recommendations. To look for predictive factors of therapeutic response to an empiric activity of I. To assess clinical situations favoring calculated treatment modalities. PATIENTS AND METHODS: Prospective monocentric study of clinical outcomes at 1 year follow-up in 86 patients with GD and MNG who received empiric I therapeutic activities (348-939 MBq)...
July 17, 2017: Nuclear Medicine Communications
keyword
keyword
97180
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"